Q-omics provides the consensus-scored ACOT6 profile across patient tissues and cancer cell-line models. ACOT6 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, ACOT6 is differentially expressed in 10, with the highest sampling consensus in KIRP. Additionally, ACOT6 RNA expression shows 13,865 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight PAAD, KIRP, and UVM as cancer lineages where ACOT6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ACOT6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ACOT6 survival associations across molecular data types. ACOT6 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (1) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ACOT6 RNA expression–survival associations across cancer types. High ACOT6 expression shows unfavorable associations in LUAD, UVM and CHOL, but favorable associations in PAAD, HNSC and READ. The PAAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for ACOT6 RNA expression.
This table summarizes ACOT6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRP for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ACOT6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ACOT6 shows lower tumor expression in KIRP, KIRC, THCA and KICH and higher tumor expression in UCEC and BRCA. The KIRP box plot shows higher ACOT6 RNA expression in normal versus tumor tissue (log2 FC = −1.350, t-test p < 0.001).
This table shows molecular features associated with ACOT6 in patient tissues and cancer cell lines. In patient samples, ACOT6 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ACOT6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BREAST.
